OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite Sells 6,443 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite sold 6,443 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $160,172.98. Following the transaction, the chief financial officer now directly owns 207,989 shares in the company, valued at approximately $5,170,606.54. This represents a 3.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

OrthoPediatrics Stock Performance

NASDAQ:KIDS traded up $0.46 during mid-day trading on Tuesday, hitting $25.42. 138,044 shares of the company’s stock traded hands, compared to its average volume of 162,840. The firm has a 50 day moving average of $24.74 and a two-hundred day moving average of $25.62. OrthoPediatrics Corp. has a 12 month low of $21.02 and a 12 month high of $35.99. The firm has a market capitalization of $617.38 million, a price-to-earnings ratio of -20.67 and a beta of 1.22. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.67 million during the quarter, compared to the consensus estimate of $51.16 million. During the same quarter in the prior year, the company earned ($0.23) EPS. On average, equities analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Institutional Trading of OrthoPediatrics

A number of hedge funds have recently modified their holdings of the company. AWM Investment Company Inc. lifted its position in shares of OrthoPediatrics by 14.8% in the 4th quarter. AWM Investment Company Inc. now owns 516,794 shares of the company’s stock worth $11,979,000 after acquiring an additional 66,779 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of OrthoPediatrics by 76.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 19,863 shares of the company’s stock worth $460,000 after acquiring an additional 8,631 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of OrthoPediatrics in the 4th quarter worth approximately $7,450,000. Numerai GP LLC bought a new stake in shares of OrthoPediatrics in the 4th quarter worth approximately $372,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of OrthoPediatrics by 25.5% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 65,292 shares of the company’s stock worth $1,513,000 after acquiring an additional 13,270 shares during the period. Institutional investors own 69.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, March 5th. Stifel Nicolaus lowered their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Finally, Truist Financial lowered their price objective on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.